Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.
Alpha emitting radionuclides are of considerable interest for targeted radioimmunotherapy. Generator supplied 213Bi emitting 8.5 MeV alpha particles with a 45.6 min half-life has been conjugated to a monoclonal antibody (HuM195-CHX-A-DTPA) for targeted therapy of leukemia in a clinical trial. The clinical dose preparation of pharmaceutical formulation by a pair of skilled radiochemists took 25 min, which corresponds, to an overall decay loss of 30% of the initial 213Bi activity eluted from the generator. In order to allow more widespread and practical clinical use of targeted 213Bi alpha particle therapy, we developed a new procedure that is simpler, more rapid and adaptable to a hospital pharmacy. The new 10 min process includes a tandem elution and labeling, and an anion exchange column purification method that can be reproducibly used.
Ma
D
D
Department of Pharmacology and Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
McDevitt
M R
MR
Finn
R D
RD
Scheinberg
D A
DA
D000512:Alpha Particles / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000627:therapeutic use; D001729:Bismuth / Q000302:isolation & purification / Q000627:therapeutic use; D002852:Chromatography, Ion Exchange / Q000379:methods; D002986:Clinical Trials as Topic; D006207:Half-Life; D006801:Humans; D018796:Immunoconjugates / Q000302:isolation & purification* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D011868:Radioisotopes / Q000302:isolation & purification / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000302:isolation & purification* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D001729:Bismuth